Research programme: droxidopa controlled-release - Lundbeck

Drug Profile

Research programme: droxidopa controlled-release - Lundbeck

Alternative Names: CR droxidopa; Northera™ controlled release; Threo-DOPS controlled release

Latest Information Update: 01 Jul 2014

Price : $50

At a glance

  • Originator Chelsea Therapeutics
  • Developer Lundbeck A/S
  • Class Amino acids; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hypotension

Most Recent Events

  • 01 Jul 2014 Discontinued - Preclinical for Hypotension in USA (PO, controlled-release)
  • 24 Jun 2014 Chelsea Therapeutics has been acquired by Lundbeck A/S
  • 16 Dec 2011 Preclinical trials in Hypotension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top